Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 2Phase 3 Interventional Results available

A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma

ClinicalTrials.gov ID: NCT03470922

Public ClinicalTrials.gov record NCT03470922. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 5:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Metastatic or Unresectable Melanoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to determine whether relatlimab in combination with nivolumab is more effective than nivolumab monotherapy in treating unresectable melanoma or melanoma that has spread.

Study identification

NCT ID
NCT03470922
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2, Phase 3
Lead sponsor
Bristol-Myers Squibb
Industry
Enrollment
714 participants

Conditions and interventions

Conditions

Interventions

Biological

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 11, 2018 (Actual)
Primary completion
Jan 25, 2021 (Actual)
Completion
Dec 15, 2030 (Estimated)
Last update posted
Sep 9, 2025

2018 – 2030

United States locations

U.S. sites
22
U.S. states
14
U.S. cities
20
Facility City State ZIP Site status
Local Institution - 0010 Tucson Arizona 85724-5024 —
Local Institution - 0020 Los Angeles California 90095 —
Coastal Integrative Cancer Care San Luis Obispo California 93401 —
Local Institution - 0116 Santa Barbara California 93105 —
Local Institution - 0012 Washington D.C. District of Columbia 20007 —
Local Institution - 0013 Jacksonville Florida 32224 —
Local Institution - 0117 Orlando Florida 32806 —
Local Institution - 0007 Tampa Florida 33612 —
Local Institution - 0038 Atlanta Georgia 30342 —
Local Institution - 0016 Chicago Illinois 60611 —
Local Institution - 0114 Fort Wayne Indiana 46804 —
Local Institution - 0077 Baltimore Maryland 21237 —
Local Institution - 0120 Baltimore Maryland 21287 —
Local Institution - 0014 Boston Massachusetts 02215 —
Local Institution - 0134 Boston Massachusetts 02215 —
Local Institution - 0015 Ann Arbor Michigan 48109 —
Local Institution - 0009 Minneapolis Minnesota 55407 —
Local Institution - 0011 Rochester Minnesota 55905 —
Local Institution - 0018 Charlotte North Carolina 28204 —
Local Institution - 0019 Allentown Pennsylvania 18103 —
Local Institution - 0076 Dallas Texas 75246 —
Local Institution - 0008 Houston Texas 77030 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 105 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03470922, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 9, 2025 · Synced Oct 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT03470922 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →